Efficacy of Combination Chemotherapy With Mitoxantrone, Vincristine, Prednisolone (MVP) for Recurrence of Breast Cancer

The study evaluated the efficacy of a combination chemotherapy regimen consisting of mitoxantrone, vincristine, and prednisolone (MVP) in 14 patients with recurrent breast cancer. The treatment showed a high objective response rate of 70% (7 out of 10 patients), with two patients maintaining a response for over 40 weeks. The primary side effect was myelosuppression, with 35.7% of patients experiencing severe leukopenia, which was managed with G-CSF therapy. Nausea and vomiting were well tolerated, likely due to prednisolone. Notably, the MVP regimen resulted in less hair loss compared to the CAF regimen, making it superior in maintaining quality of life. Overall, MVP was found to be highly effective and safe for treating recurrent breast cancer.